5. Progressive supranuclear palsy
82 clinical trials,   107 drugs   (DrugBank: 36 drugs),   60 drug target genes,   90 drug target pathways

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04539041
(ClinicalTrials.gov)
January 19, 202125/8/2020Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear PalsyA Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear PalsyProgressive Supranuclear Palsy (PSP)Drug: antisense oligonucleotide;Drug: placeboNovartis PharmaceuticalsNULLNot yet recruiting40 Years75 YearsAll64Phase 1NULL
2NCT04253132
(ClinicalTrials.gov)
January 1, 202117/12/2019Evaluation of Tolfenamic Acid in Individuals With PSP at 12-WeeksA Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Tolfenamic Acid;Drug: PlacebosNeuroTau, Inc.The Cleveland ClinicNot yet recruiting40 Years85 YearsAll24Phase 1;Phase 2United States
3NCT04658199
(ClinicalTrials.gov)
December 20201/12/2020A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyAn Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: UCB0107 (bepranemab)UCB Biopharma SRLNULLNot yet recruiting18 YearsN/AAll24Phase 1NULL
4NCT04193527
(ClinicalTrials.gov)
July 20202/12/2019A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsA Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy ControlsParkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)Drug: DaTSCAN™ Ioflupane (123I) InjectionGE HealthcarePPDNot yet recruiting40 Years80 YearsAll172Phase 3China
5NCT04008355
(ClinicalTrials.gov)
June 22, 202018/6/2019A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSPA Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: AZP2006 oral solution;Drug: Placebo oral solutionAlzProtect SASNULLRecruiting40 Years80 YearsAll36Phase 2France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03446807
(ClinicalTrials.gov)
January 202020/2/2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot yet recruiting50 YearsN/AAll32Phase 2United States
7NCT04185415
(ClinicalTrials.gov)
December 3, 20192/12/2019A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)Progressive Supranuclear PalsyDrug: bepranemab;Drug: PlaceboUCB Biopharma SRLNULLActive, not recruiting40 YearsN/AAll25Phase 1Belgium;Germany;Spain;United Kingdom
8NCT04184063
(ClinicalTrials.gov)
September 16, 201929/7/2019Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA)Progressive Supranuclear Palsy;Multiple System AtrophyDrug: NBMI;Other: PlaceboEmeraMedNULLRecruiting40 Years85 YearsAll16Phase 2Slovenia
9EUCTR2017-001590-16-DE
(EUCTR)
02/07/201911/01/2019An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy (PSP)
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie DeutschlandNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Australia;Germany
10NCT03926702
(ClinicalTrials.gov)
June 18, 201922/4/2019Tau Imaging With JNJ067Tau Imaging With JNJ067Alzheimer Disease;Mild Cognitive Impairment;Progressive Supranuclear PalsyDrug: RadiopharmaceuticalsUniversity of California, BerkeleyUniversity of California, San FranciscoActive, not recruiting50 YearsN/AAll18Early Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11JPRN-UMIN000036952
2019/06/0404/06/2019A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.18F-FDOPA, 11C-Raclopride PETNagoya City Rehabilitation AgencyNULLRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
12NCT04014387
(ClinicalTrials.gov)
June 2, 201911/4/2019Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)TreatmentDrug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsuleUniversity of California, San FranciscoUS Department of Veterans AffairsRecruiting18 YearsN/AAll60Phase 4United States
13JPRN-UMIN000036908
2019/05/3131/05/2019A dementia study by 11C-PiB, 18F-FDG PETA dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc.11C-PiB, 18F-FDG PETNagoya City Rehabilitation AgencyNULLRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
14ChiCTR2000030512
2019-05-132020-03-05Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsyClinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy progressive supranuclear palsyGold Standard:clinical diagnosis of progressive supranuclear palsy the movement disorder society criteria in 2017.(Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.).;Index test:Standard uptake value ratio of [18F]-APN-1607([18F]-PM-PBB3);Huashan Hospital, Fudan UniversityNULLRecruiting4580BothTarget condition:26;Difficult condition:0China
15JPRN-UMIN000036522
2019/04/1516/04/2019Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drugInvestigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug - Clinical trial for PSP using anticholinergic drug Progressive supranuclear palsyTrihexyphenidyl hydrochloride max.3mg for 3 months
Placebo max. 3mg for 3 months
1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya HospitalNULLRecruiting40years-oldNot applicableMale and Female32Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16JPRN-jRCTs051180214
29/03/201927/03/2019The usefulness of flutemetamol for diagnostic imaging of neurogenerative diseaseThe usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy
Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously
Itoh YoshiakiNULLRecruitingAges 20 and overN/ABoth100N/AJapan
17EUCTR2018-000506-34-SI
(EUCTR)
04/02/201909/03/2018EMERA006 - A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA).EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]NBMI Science Ltd.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
20Phase 2Slovenia
18JPRN-UMIN000034834
2019/01/0111/11/2018Detection of falling risk of progressive supranuclear palsy with inertial sensorDetection of falling risk of progressive supranuclear palsy with inertial sensor - Detection of falling risk of PSP progressive supranuclear palsyMeasurement of muscle strength, balance test, gait analysisKawasaki University of Medical WelfareNULLRecruitingNot applicableNot applicableMale and Female20Not selectedJapan,Europe
19EUCTR2016-001635-12-ES
(EUCTR)
04/07/201810/05/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Spain;Australia;Germany;Italy
20EUCTR2017-001590-16-IT
(EUCTR)
27/04/201804/11/2020An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na Progressive Supranuclear Palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: na
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
ABBVIE DEUTSCHLAND GMBH & CO. KGNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United States;Canada;Australia;Germany;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03413319
(ClinicalTrials.gov)
April 17, 201823/1/2018Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNULLCompleted18 YearsN/AAll3Phase 1United States
22NCT03545789
(ClinicalTrials.gov)
March 12, 201815/3/2018Phase 1 Test-retest Evaluation of [18F]MNI-958 PETPhase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy VolunteersHealthy Volunteers;Alzheimer Disease;Progressive Supranuclear PalsyDrug: [18F]MNI-958InvicroNULLCompleted18 Years55 YearsAll16Phase 1United States
23EUCTR2016-002554-21-GR
(EUCTR)
09/03/201802/01/2018Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Biogen Idec Research LimitedNULLNot Recruiting Female: yes
Male: yes
396Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
24NCT03391765
(ClinicalTrials.gov)
January 24, 20182/1/2018An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNULLCompleted40 YearsN/AAll143Phase 2United States;Australia;Canada;Italy;Japan;France
25NCT03625128
(ClinicalTrials.gov)
January 2, 201812/7/201818F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsPhase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsAlzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive ImpairmentDrug: F-18Chang Gung Memorial HospitalNULLCompleted20 Years90 YearsAll36Early Phase 1Taiwan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2016-001635-12-DE
(EUCTR)
23/11/201720/02/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Spain;Australia;Germany;Italy
27EUCTR2016-001635-12-FR
(EUCTR)
26/10/201717/07/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United States;France;Canada;Spain;Australia;Germany;Italy
28NCT03545126
(ClinicalTrials.gov)
August 21, 201712/3/2018Human CNS Tau Kinetics in TauopathiesHuman CNS Tau Kinetics in TauopathiesProgressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation)Other: 13C6 LeucineWashington University School of MedicineAssociation of Frontotemporal Degeneration;Tau ConsortiumRecruiting18 YearsN/AAll32United States
29EUCTR2016-002554-21-DE
(EUCTR)
18/08/201719/04/2017A study of BIIB092 in participants with Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092
Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes
459Phase 2United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of
30JPRN-JapicCTI-173627
01/8/201726/06/2017Study of BMS-986168 in Patients With Progressive Supranuclear Palsy (PASSPORT)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy Progressive Supranuclear PalsyIntervention name : BMS-986168
Dosage And administration of the intervention : BMS-986168 intravenous infusion on specified days
Control intervention name : Placebo
Dosage And administration of the control intervention : Placebo intravenous infusion on specified days
Bristol-Myers Squibb K.K.NULL4186BOTH396Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2016-002554-21-GB
(EUCTR)
21/07/201710/04/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092
Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes
459Phase 2Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France
32EUCTR2016-002554-21-AT
(EUCTR)
30/06/201720/04/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092
Biogen Idec Research LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
459Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
33EUCTR2016-002554-21-ES
(EUCTR)
08/06/201724/04/2017A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowingA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 19.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BMS-986168
INN or Proposed INN: BMS986168
Other descriptive name: BMS986168
Bristol-Myers Squibb International CorporationNULLNot RecruitingFemale: yes
Male: yes
396Phase 2United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of
34NCT03068468
(ClinicalTrials.gov)
June 1, 201727/2/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: BIIB092;Drug: PlaceboBiogenNULLTerminated41 Years86 YearsAll490Phase 2United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom
35EUCTR2016-001635-12-IT
(EUCTR)
31/05/201705/02/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
ABBVIE DEUTSCHLAND GMBH & CO. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2United States;Canada;Australia;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT03174938
(ClinicalTrials.gov)
May 15, 201728/5/2017The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
37EUCTR2017-000094-36-SE
(EUCTR)
31/03/201730/01/2017The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disordersThe BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-RO6958948
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl
Skåne University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Sweden
38NCT02985879
(ClinicalTrials.gov)
December 12, 20161/12/2016A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: placebo;Drug: ABBV-8E12AbbVieNULLCompleted40 YearsN/AAll378Phase 2United States;Australia;Canada;France;Germany;Italy;Japan;Spain
39NCT03058965
(ClinicalTrials.gov)
November 29, 201612/1/2017Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the BrainPhase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy VolunteersAlzheimer Disease;Healthy Volunteers;Progressive Supranuclear PalsyDrug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscanMolecular NeuroImagingNULLCompleted50 Years90 YearsAll12Early Phase 1United States
40NCT03080051
(ClinicalTrials.gov)
August 201612/1/2017Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the BrainPhase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy VolunteersProgressive Supranuclear Palsy;Alzheimer Disease;Healthy VolunteersDrug: [18F]MNI-952;Drug: [18F]FlorbetapirMolecular NeuroImagingNULLCompleted18 Years90 YearsAll6Early Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT02839642
(ClinicalTrials.gov)
July 26, 201630/6/2016Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyRIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical TrialProgressive Supranuclear Palsy (PSP)Drug: Rivastigmine;Drug: PlaceboAssistance Publique Hopitaux De MarseilleNULLRecruiting41 Years80 YearsAll106Phase 3France
42NCT02994719
(ClinicalTrials.gov)
March 1, 201621/12/2015Gait Analysis in Neurological DiseaseGait Pattern Analysis in Neurological DiseaseParkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington DiseaseDrug: Anti-Parkinson medication;Device: Deep Brain StimulationBeth Israel Deaconess Medical CenterNULLActive, not recruiting18 Years85 YearsAll120United States
43NCT02658916
(ClinicalTrials.gov)
February 22, 201613/1/2016Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003Supranuclear Palsy, ProgressiveDrug: BIIB092BiogenNULLTerminated41 Years86 YearsAll47Phase 1United States
44NCT02605785
(ClinicalTrials.gov)
November 20153/11/2015A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyA Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: F-18 AV 1451Mayo ClinicNULLRecruiting40 YearsN/AAll134N/AUnited States
45NCT02460094
(ClinicalTrials.gov)
October 2, 201520/5/2015Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: BIIB092;Drug: PlaceboBiogenNULLCompleted41 Years86 YearsAll48Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT02494024
(ClinicalTrials.gov)
July 201530/6/2015Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyA Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Single dose C2N-8E12;Drug: Single dose placeboC2N DiagnosticsNULLCompleted50 Years85 YearsAll32Phase 1United States
47NCT02460731
(ClinicalTrials.gov)
May 201519/5/2015Young Plasma Transfusions for Progressive Supranuclear PalsyA 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear PalsyProgressive Supranuclear PalsyBiological: Fresh Frozen PlasmaUniversity of California, San FranciscoNULLCompleted50 Years85 YearsAll6Phase 1United States
48NCT02531360
(ClinicalTrials.gov)
May 20159/6/2015Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesPhase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other TauopathiesAlzheimer's Disease (AD);Progressive Supranuclear Palsy (PSP);Cortical Basal Syndrome (CBS);Frontal Temporal Dementia (FTD)Drug: [18F]MNI-815 (MNI-815)Molecular NeuroImagingPiramal Imaging SACompleted50 Years90 YearsBoth7Phase 0United States
49NCT02422485
(ClinicalTrials.gov)
April 20159/4/2015A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear PalsyA 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: SalsalateAdam BoxerNULLUnknown status50 Years85 YearsAll10Phase 1United States
50EUCTR2013-003740-23-ES
(EUCTR)
04/02/201505/12/2013Evaluation of masitinib in the treatment of Progressive Supranuclear PalsyA prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy
MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
AB ScienceNULLNot Recruiting Female: yes
Male: yes
90Phase 3Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51EUCTR2014-000422-38-SE
(EUCTR)
19/09/201405/08/2014A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tauAn open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions.
MedDRA version: 17.0;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-AV-1451Skåne University Hospital, Region SkåneNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Sweden
52NCT02167594
(ClinicalTrials.gov)
August 12, 201417/6/2014Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy VolunteersProgressive Supranuclear Palsy;Corticobasal DegenerationDrug: Flortaucipir F18;Procedure: Brain PET scanAvid RadiopharmaceuticalsNULLCompleted50 Years85 YearsAll29Phase 1United States
53NCT02133846
(ClinicalTrials.gov)
May 20146/5/2014Safety Study of TPI-287 to Treat CBS and PSPA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear PalsyPrimary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD)Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2University of California, San FranciscoCBD Solutions;Tau ConsortiumCompleted50 Years85 YearsAll44Phase 1United States
54EUCTR2012-005539-10-DE
(EUCTR)
29/04/201418/12/2013Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Merz Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Poland;Germany
55NCT02103894
(ClinicalTrials.gov)
February 201412/2/2014Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy SubjectsAlzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;TauopathiesDrug: [18F]T807 ([18F]MNI-777)Molecular NeuroImagingInstitute for Neurodegenerative DisordersCompleted18 Years85 YearsBoth16Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT02214862
(ClinicalTrials.gov)
March 201311/8/20142-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismPilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismProgressive Supranuclear Palsy;Multi-System Atrophy;ParkinsonismDrug: [F18]-FDDNPFundacion Clinic per a la Recerca BiomédicaNULLCompleted40 YearsN/ABoth40Phase 0Spain
57NCT01824121
(ClinicalTrials.gov)
December 201231/3/2013Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of ParkinsonismAutologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical TrialProgressive Supranuclear PalsyBiological: stem cell therapyFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoNULLRecruiting40 YearsN/ABoth25Phase 1;Phase 2Italy
58JPRN-UMIN000008959
2012/11/0116/10/2012Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP)hydrogen water
pseudo-water (nitrogen filling water)
Juntendo University School of Medicine, Department of NeurologyNULLComplete: follow-up complete20years-old80years-oldMale and Female40Phase 1Japan
59EUCTR2010-019159-23-GB
(EUCTR)
22/12/201008/10/2010A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. Progressive Supranuclear Palsy
MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Allon Therapeutics IncNULLNot Recruiting Female: yes
Male: yes
300Phase 2;Phase 3France;United States;Canada;Australia;Germany;United Kingdom
60EUCTR2010-019159-23-DE
(EUCTR)
08/11/201027/08/2010A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. Progressive Supranuclear Palsy
MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Davunetide
Product Code: AL-108
INN or Proposed INN: Davunetide
Allon Therapeutics IncNULLNot RecruitingFemale: yes
Male: yes
300Phase 2;Phase 3France;United States;Canada;Australia;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61NCT01110720
(ClinicalTrials.gov)
October 201023/4/2010Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyA Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Davunetide;Drug: PlaceboAllon TherapeuticsNULLCompleted41 Years85 YearsBoth313Phase 2;Phase 3United States;Australia;Canada;France;Germany;United Kingdom
62NCT01537549
(ClinicalTrials.gov)
September 14, 20109/1/2012Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear PalsyAn Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial BiomarkersProgressive Supranuclear PalsyDrug: alpha-lipoic acid and L-acetyl carnitineWeill Medical College of Cornell UniversityNULLCompleted40 Years75 YearsAll11Phase 1;Phase 2United States
63EUCTR2008-007520-26-DE
(EUCTR)
24/06/201013/11/2009A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy
Trade Name: Azilect
INN or Proposed INN: Rasagilin
Other descriptive name: RASAGILINE MESILATE
Klinikum der Universität MünchenNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany
64NCT01056965
(ClinicalTrials.gov)
January 201021/1/2010Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyA 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted TauopathiesPredicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent AphasiaDrug: davunetide (AL-108, NAP);Drug: Placebo nasal sprayUniversity of California, San FranciscoNULLCompleted40 Years85 YearsAll12Phase 1United States
65NCT01187888
(ClinicalTrials.gov)
January 201020/8/2010Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)Progressive Supranuclear PalsyDrug: Rasagiline;Drug: Sugar pillProf. Dr. Stefan LorenzlTeva Pharmaceutical Industries;Ludwig-Maximilians - University of MunichTerminated50 Years80 YearsBoth44Phase 3Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT01049399
(ClinicalTrials.gov)
December 200913/1/2010Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyA Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: tideglusib;Drug: placeboNoscira SAi3 ResearchCompleted40 Years85 YearsBoth146N/AUnited States;Germany;Spain;United Kingdom
67EUCTR2009-013097-40-ES
(EUCTR)
17/11/200929/07/2009Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderadaEstudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada Parálisis Supranuclear Progresiva leve o moderada
MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125Spain;Germany;United Kingdom
68EUCTR2009-013097-40-DE
(EUCTR)
06/11/200930/07/2009A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROSA double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125United Kingdom;Spain;Germany
69EUCTR2009-013097-40-GB
(EUCTR)
30/10/200923/07/2009 A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy
Noscira S.A.NULLNot Recruiting Female: yes
Male: yes
140Phase 2Spain;Germany;United Kingdom
70NCT00703677
(ClinicalTrials.gov)
September 200820/6/2008A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationA Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationProgressive Supranuclear Palsy;Corticobasal DegenerationDrug: LithiumWestatNational Institute of Neurological Disorders and Stroke (NINDS)Completed40 Years80 YearsAll17Phase 1;Phase 2United States;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT00522015
(ClinicalTrials.gov)
February 200827/8/2007Efficacy Study for Treatment of Dementia in Progressive Supranuclear PalsyRivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 StudyProgressive Supranuclear Palsy;DementiaDrug: rivastigmineUniversity Hospital TuebingenNULLRecruiting50 YearsN/ABoth20Phase 2Germany
72EUCTR2006-006166-42-DE
(EUCTR)
17/07/200702/01/2007Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.Trade Name: Exelon 1,5 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 3,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 6,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
University of TuebingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2-Germany
73NCT00385710
(ClinicalTrials.gov)
November 200610/10/2006Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: valproic acid;Drug: PlaceboNantes University HospitalNULLCompleted45 Years75 YearsBoth28Phase 2France
74NCT00382824
(ClinicalTrials.gov)
September 200628/9/2006Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind StudyProgressive Supranuclear PalsyDietary Supplement: Coenzyme Q10;Other: PlaceboLahey ClinicNULLCompleted30 YearsN/AAll61N/AUnited States
75NCT00328874
(ClinicalTrials.gov)
May 200621/5/2006Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear PalsyMono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Coenzyme Q10German Parkinson Study Group (GPS)MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical CenterCompleted40 Years85 YearsAll20Phase 2Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76EUCTR2005-000574-40-DE
(EUCTR)
24/04/200624/01/2006Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/ABrain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP.Product Name: Coenzym Q10 Nanodispersion
Product Code: ASK Nr. 21972
INN or Proposed INN: Ubidecarenon
Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon
Kompetenznetz Parkinson e.V.NULLNot RecruitingFemale: yes
Male: yes
30Germany
77NCT00139373
(ClinicalTrials.gov)
May 200530/8/2005Study of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsyStudy of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: donepezilGroupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting30 Years80 YearsBoth16Phase 2France
78NCT00605930
(ClinicalTrials.gov)
April 200414/1/2008A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.Progressive Supranuclear PalsyDietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: PlaceboUniversity of LouisvilleNULLCompletedN/AN/AAll20N/AUnited States
79NCT00532571
(ClinicalTrials.gov)
January 200418/9/2007Effects of Coenzyme Q10 in PSP and CBDEffects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot StudyProgressive Supranuclear Palsy;Neurological DisordersDrug: CoQ10Lahey ClinicNULLCompleted40 YearsN/AAllPhase 2;Phase 3United States
80NCT00005903
(ClinicalTrials.gov)
June 20007/6/2000Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear PalsyDose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSPProgressive Supranuclear PalsyDrug: GDNF & Synchro Med Infusion SystemNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth15Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81NCT00211224
(ClinicalTrials.gov)
April 200013/9/2005Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)Multiple System Atrophy;Progressive Supranuclear PalsyDrug: RiluzoleKing's College LondonAssistance Publique - Hôpitaux de Paris;University of Ulm;Aventis PharmaceuticalsTerminated30 Years80 YearsBoth800Phase 3United Kingdom
82EUCTR2016-002554-21-FR
(EUCTR)
15/06/2018A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowingA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BMS-986168
INN or Proposed INN: BMS986168
Other descriptive name: BMS986168
Bristol-Myers Squibb International CorporationNULLNAFemale: yes
Male: yes
396Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of